🎉 M&A multiples are live!
Check it out!

Vaxart Valuation Multiples

Discover revenue and EBITDA valuation multiples for Vaxart and similar public comparables like Benevolent AI, Pharming, and Julphar.

Vaxart Overview

About Vaxart

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.


Founded

1969

HQ

United States of America
Employees

105

Website

vaxart.com

Financials

LTM Revenue $21.9M

LTM EBITDA n/a

EV

$47.7M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Vaxart Financials

Vaxart has a last 12-month revenue of $21.9M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Vaxart achieved revenue of $28.7M and an EBITDA of -$54.9M.

Vaxart expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Vaxart valuation multiples based on analyst estimates

Vaxart P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $7.4M $28.7M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$72.1M -$54.9M XXX XXX XXX
EBITDA Margin -978% -191% XXX XXX XXX
Net Profit -$108M -$82.5M XXX XXX XXX
Net Margin -1460% -287% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Vaxart Stock Performance

As of April 15, 2025, Vaxart's stock price is $0.

Vaxart has current market cap of $81.9M, and EV of $47.7M.

See Vaxart trading valuation data

Vaxart Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$47.7M $81.9M XXX XXX XXX XXX $-0.33

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Vaxart Valuation Multiples

As of April 15, 2025, Vaxart has market cap of $81.9M and EV of $47.7M.

Vaxart's trades at 2.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Vaxart's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Vaxart and 10K+ public comps

Vaxart Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $47.7M XXX XXX XXX
EV/Revenue 1.7x XXX XXX XXX
EV/EBITDA -0.9x XXX XXX XXX
P/E -1.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Vaxart Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Vaxart Valuation Multiples

Vaxart's NTM/LTM revenue growth is -78%

Vaxart's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Vaxart's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Vaxart's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Vaxart and other 10K+ public comps

Vaxart Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 289% XXX XXX XXX XXX
EBITDA Margin -191% XXX XXX XXX XXX
EBITDA Growth -24% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -270% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 72% XXX XXX XXX XXX
R&D Expenses to Revenue 259% XXX XXX XXX XXX
Opex to Revenue 331% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Vaxart Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Vaxart M&A and Investment Activity

Vaxart acquired  XXX companies to date.

Last acquisition by Vaxart was  XXXXXXXX, XXXXX XXXXX XXXXXX . Vaxart acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Vaxart

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Vaxart

When was Vaxart founded? Vaxart was founded in 1969.
Where is Vaxart headquartered? Vaxart is headquartered in United States of America.
How many employees does Vaxart have? As of today, Vaxart has 105 employees.
Who is the CEO of Vaxart? Vaxart's CEO is Mr. Steven Lo.
Is Vaxart publicy listed? Yes, Vaxart is a public company listed on NAS.
What is the stock symbol of Vaxart? Vaxart trades under VXRT ticker.
When did Vaxart go public? Vaxart went public in 1990.
Who are competitors of Vaxart? Similar companies to Vaxart include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Vaxart? Vaxart's current market cap is $81.9M
What is the current revenue of Vaxart? Vaxart's last 12-month revenue is $21.9M.
What is the current EV/Revenue multiple of Vaxart? Current revenue multiple of Vaxart is 2.2x.
What is the current revenue growth of Vaxart? Vaxart revenue growth between 2023 and 2024 was 289%.
Is Vaxart profitable? Yes, Vaxart is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.